![]()
|
|
||||||||
J. Biol. Chem., Vol. 276, Issue 47, 44069-44077, November 23, 2001
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
B Activation Pathways*
§,
,
,
,
,
From the
Molecular Cell Biology Laboratory,
Department of Genetics, Smurfit Institute, Trinity College, Dublin 2, Ireland and the ¶ Medical Research Council Toxicology Unit,
University of Leicester, Leicester LE19HN, United Kingdom
Received for publication, August 2, 2001, and in revised form, September 6, 2001
| |
ABSTRACT |
|---|
|
|
|---|
Proteins possessing the caspase recruitment
domain (CARD) motif have been implicated in pathways leading to
activation of caspases or NF- The caspase recruitment domain
(CARD)1 is a protein-protein
interaction motif, comprising a bundle of six Caspases that participate in apoptosis appear to be organized into
hierarchical cascades, with those containing CARD motifs (or the
related death effector domain (DED) motif) within their pro-domain
regions occupying positions at the apex of caspase activation cascades
(3, 5, 7-9). Activation of apical (CARD- or DED-containing) caspases
appears to be achieved through aggregation of the latter via
interactions between adaptor molecules that contain similar CARD or DED
motifs (5, 8, 10). This strategy serves to increase the local
concentration of apical caspases and allow processing of adjacent
caspase molecules in trans, a process that has been termed
the "induced-proximity model" (10).
The CARD motif does not appear to be restricted to caspases and their
adaptor proteins, however. Recently, several CARD-containing proteins
have been identified (Bcl10, CARD4/Nod1, Nod2, CARD10, CARD11, CARD14),
the function of which appears to be directed primarily toward
activation of the NF- Several other CARD family proteins have been described that also appear
to drive NF- More recently, CARD-containing homologues of Apaf-1 (CARD4/Nod1, Nod2)
have also been shown to promote NF- Thus, CARD-containing proteins occur repeatedly in stress response
pathways that lead to activation of either caspases or NF- Plasmids--
All plasmid constructs were generated using
standard polymerase chain reaction procedures with primers designed to
incorporate appropriate restriction enzyme sites. Polymerase chain
reaction products were then digested and cloned into pcDNA3
(Invitrogen), pEGFP-C3 (CLONTECH), or pGEX4TK2
(Amersham Pharmacia Biotech), as indicated in the text. Plasmids were
sequenced on an ABI 310 automated sequencer using ABI PRISM dye
terminator cycle sequencing kits (PerkinElmer Life Sciences), according
to the manufacturer's instructions.
Antibody Generation and Affinity Purification--
A polyclonal
anti-CARDINAL antibody was generated by repeated immunization of
rabbits with a GST-CARDINAL fusion protein (amino acids 321-431).
Antiserum was purified by running over an Affi-Gel (Bio-Rad) affinity
column containing the immobilized GST-CARDINAL-(321-431) fusion
protein, followed by elution of bound antibody with 100 mM
glycine, pH 2.8.
Western Blot Analysis of CARDINAL Expression on Human Tissues and
Human Tumor Cell Lines--
Total protein lysates (100 µg/lane)
prepared from a range of normal human tissues
(CLONTECH) were electrophoresed on 12%
polyacrylamide gels under standard SDS-polyacrylamide gel
electrophoresis conditions. Total protein lysates were also prepared
from a panel of human tumor cell lines by lysing cells at
107/ml in SDS-polyacrylamide gel electrophoresis sample
buffer, followed by electrophoresis of samples (~50 µg/lane) on
12% polyacrylamide gels. Proteins were then transferred onto 0.45-µm
nitrocellulose membrane and were probed for CARDINAL or actin
expression using specific antibodies.
Luciferase Reporter Assays--
Typically, 2 × 105 HEK 293T cells were transfected with appropriate
plasmid combinations using the standard calcium phosphate precipitation
method. For NF-
24-48 h after transfection, medium was removed from the transfected
cells which were then washed with PBS, pH 7.2. Cells were lysed by
addition of 150 µl of PBS, followed by an equal volume of luciferase
reporter/lysis reagent (luciferase constant light signal reporter gene
assay kit; Roche Molecular Biochemicals). The light emitted from
triplicate 50-µl aliquots of cell lysates was then measured in black
96-well plates by luminometry. Transfection efficiencies were
normalized by measuring Transient Transfection and Co-immunoprecipitation
Assays--
Cells (HEK293T) were seeded at a density of 2 × 106 cells/10-cm plate the day before transfection. Cells
were transfected with 5-10 µg of appropriate plasmids according to
the established calcium phosphate precipitation method, and DNA
complexes were typically allowed to remain on cells until harvesting.
Cell lysates were made 24-48 h after transfection by resuspending
cells in 800 µl of IP lysis buffer (50 mM Tris-Cl, pH
8.0, 150 mM NaCl, 1% Nonidet P-40) containing 100 µM phenylmethylsulfonyl fluoride, 10 µg/ml leupeptin,
and 1 µg/ml aprotinin. Following centrifugation, clarified lysates
were subjected to immunoprecipitation using 1 µg of the appropriate
antibody and 30 µl of agarose-coupled protein A/G (Santa Cruz).
Samples were incubated with rotation for 3-6 h at 4 °C, and
complexes were washed three to four times in IP lysis buffer containing
0.1% Nonidet P-40. Immunoprecipitates were then analyzed by
immunoblotting using appropriate primary and secondary antibodies.
Subcellular Localization--
MCF-7 cells were plated on
eight-well chamber slides at a density of 1 × 105
cells/well. The following day, cells were transfected by lipofection using Fugene-6 transfection reagent (Roche Molecular Biochemicals), according to the manufacturer's instructions. Typically, 200 ng of
pEGFP-C3-based plasmids encoding GFP or GFP-CARDINAL and its derivatives were transfected per treatment. Approximately 18 h after transfection, cells were stained with Mitotracker red CMXRos (100 nM) for 15 min at 37 °C before fixation in 3.8%
formaldehyde in PBS, pH 7.2, for 20 min at room temperature. Cells were
then rinsed in PBS, and nuclei were stained with Hoechst 33258 (0.25 g/ml) for 20 min before mounting onto glass coverslips using
Vectashield (Vector Laboratories). Optical sections were taken using
argon-krypton, UV lasers, and a Leica TCS-4D confocal imaging system.
Apoptosis Assays--
MCF-7 cells were plated at a density of
105 cells/well in six-well plates and transfected the
following day with Fugene-6 (2 µl/well). Typically, 800 ng of
pcDNA3-based plasmids were transfected along with 50 ng of
pCMV Identification of CARDINAL--
To identify novel CARD-containing
proteins, we searched the public expressed sequence tag data bases for
clones encoding CARD motifs using the N-terminal prodomain of human
caspase-1 (amino acids 1-119) as the query sequence. This search
identified a predicted protein encoded by expressed sequence tag clone
KIAA0955 (GenBankTM accession no. BAA76799) in the KDRI brain genomic
data base, with significant homology to the CARD of caspase-1 within its C terminus. Sequence analysis of this clone revealed an open reading frame that encoded a predicted protein of 431 amino acids (Fig.
1, A and B). BLASTP
searches with the predicted protein sequence encoded by this clone
revealed significant homology with the CARD domains of several other
CARD proteins (Fig. 1C). Furthermore, CARDINAL also
exhibited a high degree of homology with the C terminus of the recently
described Apaf-1/Nod-1 family member DEFCAP/NAC (Fig. 1D).
We have designated this protein CARDINAL, for CARD inhibitor of NF- Tissue Expression of CARDINAL--
To explore the tissue
distribution of CARDINAL, we generated a polyclonal antibody by
immunizing rabbits with a GST-CARDINAL (amino acids 321-431) fusion
protein. This antibody specifically recognized CARDINAL migrating as a
single band of ~50 kDa, which is close to the predicted molecular
mass of 49 kDa (Fig. 2A). Western blot analysis using affinity-purified anti-CARDINAL antibody revealed that CARDINAL was expressed in several normal human tissues, including; heart, kidney, liver, lung, ovary, placenta, and testis (Fig. 2B). The highest levels of CARDINAL expression were
found in lung, ovary, testis, and placenta with low or absent
expression in brain, skeletal muscle, and spleen. Western blot analysis
of CARDINAL expression in a panel of transformed human cell lines revealed a high level of expression in the MCF-7 breast carcinoma cell
line, with intermediate levels of expression in the monocytic THP.1 and
U937 cell lines and low levels of expression in the T and B
lymphoblastoid cell lines CEM and BJAB (Fig. 2C).
CARDINAL Subcellular Distribution--
To explore the subcellular
localization of CARDINAL, an N-terminally EGFP-tagged CARDINAL
expression plasmid was transiently transfected into MCF-7 cells.
CARDINAL exhibited a mainly diffuse cytoplasmic distribution pattern,
with a fraction of CARDINAL expression also detectable within the
nucleus (Fig. 3). No significant overlap
between CARDINAL and Mitotracker staining was observed. A similar
subcellular distribution pattern of CARDINAL expression was also
observed in 293T and HeLa cells (data not shown).
CARDINAL Fails to Promote Apoptosis or NF-
We next explored whether CARDINAL could promote activation of NF- CARDINAL Is an Inhibitor of Multiple Pathways to NF- Inhibition of IL-1- and TNF-associated NF- Deletional Analysis of CARDINAL--
To explore the region within
CARDINAL responsible for inhibition of NF-
However, relative to the EGFP control, EGFP-tagged full-length CARDINAL
potently inhibited NF- CARDINAL Interacts with IKK
Thus, we asked whether CARDINAL could directly bind to IKK Here we report the identification of CARDINAL, a CARD-containing
protein that exhibits potent NF- As outlined in the Introduction, many recent studies have implicated
CARD-containing proteins as signaling components of pathways that
result in NF- A different route to NF- Strikingly, Nod1/CARD4 and Nod2 have recently been implicated as
intracellular sensors for bacterial lipopolysaccharide, through binding
of this conserved component of Gram-negative bacteria through their
leucine-rich repeat regions (32). Furthermore, Nod1/CARD4 and Nod2 also
share significant homology with plant disease resistance (R) proteins
that also act as intracellular sensors of pathogen products. Thus, the
Nod1/Apaf-1 family appear to be involved in host defense responses to
different forms of cellular stress (bacterial infection, cell damage)
where the outcome is either caspase activation and apoptosis (in the
case of Apaf-1), or NF- Given the emerging role for CARD-family proteins as signaling
intermediaries in multiple pathways that result in NF- The significance of the extensive homology between the N
terminus of CARDINAL and the C terminus of DEFCAP/NAC also remains unclear. DEFCAP/NAC is a member of the Apaf-1/Nod1 family of
CARD/nucleotide binding domain proteins (33, 34). There is disagreement
as to the specific binding partners of DEFCAP/NAC (caspase-2/caspase-9 versus Apaf-1) and whether this protein promotes caspase
activation and apoptosis via direct or indirect means (33, 34). The
domain structure of NAC/DEFCAP would strongly suggest that this protein is likely to act as a sensor for pathogen products, akin to Nod1/CARD4 and Nod2, although this remains to be determined. The latter
possibility introduces a scenario where CARDINAL may act to antagonise
signals routed through DEFCAP/NAC by competing for the same C-terminal binding partners of the latter.
Clearly, there are many interesting questions concerning CARDINAL
function that require further investigation. In the present study, we
have provided data to suggest that CARDINAL can antagonize NF-
B in the context of apoptosis or
inflammation, respectively. Here we report the identification of a
novel protein, CARDINAL, that contains a CARD motif and also exhibits a
high degree of homology to the C terminus of DEFCAP/NAC, a recently described member of the Apaf-1/Nod-1 family. In contrast with the
majority of CARD proteins described to date, CARDINAL failed to promote
apoptosis or NF-
B activation. Rather, CARDINAL potently suppressed
NF-
B activation associated with overexpression of TRAIL-R1,
TRAIL-R2, RIP, RICK, Bcl10, and TRADD, or through ligand-induced stimulation of the interleukin-1 or tumor necrosis factor receptors. Co-immunoprecipitation experiments revealed that CARDINAL interacts with the regulatory subunit of the I
B kinase (IKK) complex, IKK
(NEMO), providing a molecular basis for CARDINAL function. Thus, CARDINAL is a novel regulator of NF-
B activation in the
context of pro-inflammatory signals.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-helices, that was first identified in caspases and their associated adaptor molecules (1). Caspases, cysteine aspartic acid-specific proteases, play a key
coordinating role in apoptosis by targeting a subset of cellular
proteins for limited proteolysis (2-6).
B transcription factor, rather than caspases
(11-19). The prototypical member of this family, Bcl10 (cE10, CIPER,
CLAP, CARMEN), has recently been found to be essential for NF-
B
activation in the context of ligation of the T or B cell receptors for
antigen (20). The viral Bcl10 homologue, vCLAP (vE10), is also a potent
activator of NF-
B and has been shown to interact with the regulatory
subunit of the I
B kinase complex, IKK
(21). Cellular Bcl10 may
also drive NF-
B activation via recruitment of IKK
, although this
remains to be demonstrated.
B activation through association with Bcl10 (16, 18,
19). Thus, Bcl10 appears to be an important convergence point for
CARD-containing proteins that regulate NF-
B activation (see Ref. 22
for a recent review). In the latter cases, CARD:CARD interactions
between Bcl10 and its binding partners may facilitate activation of the
IKK complex through recruitment of IKK
, followed by the IKK
and
IKK
subunits.
B activation through recruitment
of the CARD-containing kinase RICK (CARDIAK/RIP-2; Refs. 17 and 23).
Moreover, RICK has also been shown to interact with IKK
providing a
means whereby recruitment of RICK may result in NF-
B activation
through downstream activation of the IKK complex (23).
B.
Activation of the latter molecules results in either apoptosis or
transcription of pro-inflammatory genes, responses that are consistent
with the preservation of the integrity of multicellular organisms.
Here, we describe a novel CARD-containing protein, CARDINAL, which does
not appear to be involved in activation of either caspases or NF-
B.
Instead, CARDINAL was found to inhibit divergent NF-
B activation
signals and to interact with the regulatory subunit of the I
B kinase
complex, IKK
/NEMO. Thus, CARDINAL may play a role in setting a
threshold for NF-
B activation, or in limiting the duration of the
NF-
B response in the context of pro-inflammatory signals.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
B reporter assays, cells were transfected with 100 ng
of pGL35X
B-luc, 50 ng of pCMV
gal, and amounts of the relevant
expression plasmids as described in the figure legends. Total plasmid
amounts per well were made equal using pcDNA3 empty vector. The p53
reporter assays were set up in the same way using 100 ng of
p53-luciferase reporter plasmid (Stratagene) and 50 ng of pCMV
Gal.
In some experiments, because of the pro-apoptotic effects associated
with some NF-
B-inducing molecules (RIP, TRADD, TRAIL-R1, etc.),
z-VAD-fmk (5 µM) was added to all wells to minimize loss
of cells during the experiment.
-galactosidase activities, as follows.
Briefly, 50 µl of cell lysate was incubated with 0.66 mg/ml
O-nitrophenyl
-D-galactopyranoside in 1 ml of Z buffer (60 mM Na2HPO4, 40 mM NaH2PO4, 10 mM KCl,
1 mM MgSO4, pH 7) at 37 °C until a color
change developed (typically 30 min). The reaction was stopped by
addition of 300 µl of 1 M Na2CO3
followed by measurement of
-galactosidase activity at
A420.
gal reporter plasmid (CLONTECH). Cells were
washed briefly in serum-free medium 6 h after transfection, and
medium was replaced. 24-48 h after transfection, cells were fixed and
stained for
-galactosidase expression as described previously (24).
A minimum of 300 blue (transfected) cells/well were assessed for
features of apoptosis using standard criteria.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
B-activating
ligands (see below).

View larger version (75K):
[in a new window]
Fig. 1.
Sequence analysis of CARDINAL and alignment
with proteins possessing similar motifs. A, the
CARDINAL open reading frame encodes a predicted protein of 431 amino
acids. The region encompassing the CARD motif (amino acids 347-431) is
underlined. B, schematic representation of the
domain structure of human CARDINAL. Numbers represent amino
acid positions. C, alignment of the CARD region of CARDINAL
(amino acids 341-431) with that of the CARD-containing proteins
caspase-1, ASC, caspase-2, CARD4/Nod1, RAIDD, ICEBERG, NAC/DEFCAP.
Amino acid positions are indicated to the left of the
alignment. D, alignment of CARDINAL with DEFCAP/NAC
.
Amino acids identical to the consensus are shaded
black; conservative substitutions are
boxed.

View larger version (68K):
[in a new window]
Fig. 2.
CARDINAL protein expression in human tissues
and transformed cell lines. A, validation of anti-CARDINAL
antibody. A rabbit polyclonal antibody against CARDINAL was generated
and affinity-purified as described under "Experimental Procedures."
HEK 293T cells were transfected with the indicated amounts of
pcDNA3 empty vector or pcDNA3-CARDINAL, and lysates made
24 h later. Equal amounts of total protein (~50 µg) were then
analyzed by immunoblotting for CARDINAL expression, or actin as a
loading control, as indicated. B, CARDINAL protein
expression in adult human tissues. Whole cells lysates (100 µg/lane)
from the indicated human tissues were analyzed for CARDINAL expression
by immunoblotting. Blots were stripped and re-probed for actin.
C, CARDINAL protein expression in human tumor cell lines.
Total protein lysates (50 µg/lane) were prepared from the indicated
human cell lines and assessed for CARDINAL expression by immunoblot.
Duplicate blots were probed for
-actin as a loading control, as
indicated.

View larger version (65K):
[in a new window]
Fig. 3.
CARDINAL subcellular distribution. An
expression plasmid encoding EGFP-tagged CARDINAL was transfected into
MCF-7 cells, as described under "Experimental Procedures." 18 h after transfection, cells were stained with Mitotracker/Hoechst
33342, followed by examination under confocal microscopy. CARDINAL
expression is indicated in green, mitochondria appear
red, and nuclei are stained blue.
B Activation--
As
discussed in the Introduction, most CARD-containing proteins that have
been described to date have been implicated in pathways that lead to
activation of caspases (and consequent apoptosis), or activation of the
NF-
B transcription factor. Thus, we explored whether CARDINAL could
promote either apoptosis or NF-
B activation upon transient
overexpression. Fig. 4A
illustrates that, whereas transient overexpression of the well
established pro-apoptotic proteins FADD, TRADD, Bax, or RIP resulted in
extensive apoptosis of MCF-7 cells, overexpression of CARDINAL failed
to promote apoptosis under the same conditions. Dose-response
experiments performed over a wide range of pcDNA3-CARDINAL plasmid
concentrations yielded similar results (data not shown).

View larger version (20K):
[in a new window]
Fig. 4.
Assessment of apoptosis and
NF-
B activation associated with CARDINAL
overexpression. A, MCF-7 cells were transfected with
pcDNA3 empty vector (800 ng), or the same amount of expression
plasmids encoding CARDINAL, FADD, Bax, TRADD, or RIP as indicated,
along with 50 ng of
-galactosidase reporter plasmid (pCMV
).
48 h after transfection, the percentage of
-galactosidase-positive (blue) cells exhibiting apoptotic features
was determined from a minimum of 300 cells/well. Results are
representative of three separate experiments. B, using
standard calcium phosphate precipitation, HEK293T cells were
transfected either with 1 µg of empty vector or with 1 µg of
plasmids encoding RIP, TRADD, DR5, RICK, alongside the indicated
amounts of pcDNA3-CARDINAL plasmid. All wells also received 200 ng
of pGL35X
B-luc and 100 ng of pCMV
reporter plasmids and were
normalized to the same amount of total DNA using pcDNA3 empty
vector. 24 h after transfection, cell lysates were prepared and
luciferase activities associated with activation of the NF-
B-driven
luciferase reporter were measured, in triplicate, as described under
"Experimental Procedures." Luciferase activity values were
normalized to
-galactosidase activity values to correct for
variability in transfection efficiency between wells. Cell lysates
prepared from CARDINAL-transfected cells were also assessed for
CARDINAL expression by immunoblotting (inset). Results are
representative of at least six separate experiments.
B.
Expression plasmids encoding CARDINAL, RIP, TRADD, TRAIL-R2 (DR5), or
RICK were transfected into HEK293T cells along with a luciferase
reporter construct under the control of five tandemly repeated NF-
B
binding elements. Using this reporter system, significant NF-
B
activity was detected upon transfection with RIP, TRADD, TRAIL-R2, and
RICK, as expected (Fig. 4B). However, CARDINAL failed to
activate NF-
B at any of the plasmid concentrations tested, despite
high levels of CARDINAL protein expression being readily detectable in
these cells (Fig. 4B, inset).
B
Activation--
While investigating the ability of CARDINAL to
activate NF-
B, we noticed that CARDINAL-transfected cells
consistently produced NF-
B-driven luciferase reporter gene activity
below the basal level of NF-
B activity seen with the empty vector
control (data not shown). This suggested that CARDINAL may act to
suppress rather than promote NF-
B activation. Thus, we
co-transfected expression plasmids for CARDINAL along with a panel of
established NF-
B activators (RIP, TRADD, DR4/TRAIL-R1, DR5/TRAIL-R2,
Bcl10) to assess whether CARDINAL could suppress the ability of the
latter to activate NF-
B. Fig.
5A illustrates that CARDINAL
substantially attenuated NF-
B-dependent luciferase
reporter gene activity associated with transient overexpression of RIP,
TRADD, TRAIL-R1 (DR4), TRAIL-R2 (DR5), and Bcl10. CARDINAL also
dose-dependently inhibited RICK-induced NF-
B activation
(Fig. 5B). In contrast, CARDINAL did not influence activation of a luciferase reporter gene placed under the control of
p53-responsive promoter elements, demonstrating that the effects of
CARDINAL were specific to NF-
B (Fig. 5C).

View larger version (30K):
[in a new window]
Fig. 5.
CARDINAL is an inhibitor of multiple pathways
to NF-
B activation. A,
left panel, HEK293T cells were transfected with 1 µg of expression plasmids encoding, RIP, TRADD, DR4, or DR5, along
with 2 µg of either empty vector (black
shading) or 2 µg of pcDNA3-CARDINAL
(hatched shading). Right
panel, HEK293T cells were transfected with 1 µg of an
expression plasmid encoding Bcl10, along with 1 µg of either empty
vector (black shading) or 1 µg of
pcDNA3-CARDINAL (hatched shading). In both
cases, all wells also received 100 ng of pGL35X
B-luc and 50 ng of
pCMV
reporter plasmids and were normalized to the same amount of
total DNA using pcDNA3 empty vector. 24 h after transfection,
cells were lysed and NF-
B-driven luciferase reporter activities were
measured, in triplicate, as described under "Experimental
Procedures." Luciferase activity values were normalized to
-galactosidase activity values to correct for variability in
transfection efficiency between wells. Results are representative of
three separate experiments. B, HEK293T cells were
transfected with 1 µg of RICK expression plasmid, along with the
indicated amounts of pcDNA3-CARDINAL. All wells also received the
pGL35X
B-luc (100 ng) and pCMV
(50 ng) reporter plasmids.
Luciferase assays were performed 24 h after transfection and
normalized to correct for transfection efficiency as described above.
Lysates were also assessed for CARDINAL expression by immunoblot using
anti-CARDINAL rabbit polyclonal antibody (lower
panel). C, CARDINAL does not inhibit
transactivation of a p53-responsive luciferase reporter gene. HEK 293T
cells were transfected with 500 ng of empty vector or 500 ng of a p53
expression plasmid, along with 1 µg of empty vector (black
shading) or 1 µg or CARDINAL expression plasmid
(hatched shading). All wells also received 100 ng
of p53-luc and 50 ng of pCMV
reporter plasmids. 24 h after
transfection, cells were lysed and p53-driven luciferase reporter
activities were measured (in triplicate) and normalized to
-galactosidase activity values. Results are representative of three
separate experiments.
B Activity by
CARDINAL--
We next explored whether CARDINAL could inhibit NF-
B
activation associated with engagement of the IL-1 or TNF receptors with their natural ligands. Thus, HEK293T cells were transiently transfected with either empty vector (pcDNA3), pcDNA3-CARDINAL, or the
poxvirus-derived caspase-inhibitor CrmA, along with a NF-
B-driven
luciferase reporter plasmid. Transfected cells were incubated for
24 h to allow expression of the transfected genes, followed by
stimulation with either recombinant IL-1
or TNF
for 6 h.
Fig. 6 shows that, whereas CrmA
expression failed to block NF-
B activation associated with IL-1
or TNF
-treatment as expected, CARDINAL substantially suppressed NF-
B activation in both contexts.

View larger version (21K):
[in a new window]
Fig. 6.
CARDINAL inhibits IL-1- and TNF-associated
NF-
B activation. HEK293T cells were
transfected with either pCDNA3 empty vector (2 µg) or the same
amounts of pcDNA3-CARDINAL, or pcDNA3-CrmA expression plasmids,
as indicated. All wells also received the pGL35X
B-luc (100 ng) and
pCMV
(50 ng) reporter plasmids. 24 h after transfection,
cultures were stimulated for 6 h with 20 ng/ml IL-1 or TNF, or
were left untreated as shown. Cells were then lysed and NF-
B
activation assays performed as described under "Experimental
Procedures."
B activation, we
constructed EGFP-tagged versions of full-length CARDINAL, a deletion
mutant lacking the C-terminal CARD motif (EGFP-CARDINAL-(1-320)), and
a mutant lacking the N-terminal NAC/DEFCAP-homologous region
(EGFP-CARDINAL-(321-431); Fig.
7A). As in previous
experiments, neither EGFP-tagged CARDINAL nor its deletion mutants were
capable of spontaneously activating the NF-
B-driven luciferase
reporter plasmid (Fig. 7B, left
panel).

View larger version (32K):
[in a new window]
Fig. 7.
Deletional analysis of CARDINAL.
A, schematic representation of EGFP epitope-tagged CARDINAL
deletion mutants. The CARD region is shaded in
black. B, HEK293T cells were transfected with
either EGFP vector (2 µg), or the same amount of the indicated
EGFP-tagged CARDINAL expression plasmids, as indicated. All wells also
received the pGL35X
B-luc (100 ng) and pCMV
(50 ng) reporter
plasmids. 24 h after transfection, cultures were stimulated for
6 h with 20 ng/ml IL-1 or TNF, or were left untreated as shown.
Cells were then lysed and NF-
B activation assays performed as
described under "Experimental Procedures." C, expression
of EGFP and EGFP-CARDINAL deletion mutants under the conditions
described in panel B. Total cell lysates (50 µg/lane) were
analyzed by immunoblot with an anti-GFP monoclonal antibody.
B-dependent reporter gene activity associated with exposure of HEK293T cells to either recombinant IL-1
or TNF
(Fig. 7B). This inhibition was eliminated by
removal of the N-terminal region of CARDINAL (amino acids 1-320), as
the EGFP-CARDINAL-(321-431) mutant encoding the CARD region failed to
suppress NF-
B activation associated with IL-1
or TNF
treatment (Fig. 7B). The failure of EGFP-CARDINAL-(321-431) to
suppress IL-1- or TNF-associated NF-
B activation signals was not
because of decreased expression levels of the latter, as this mutant
was expressed at levels comparable with, or even higher than, that of
the other EGFP-tagged constructs (Fig. 7C). Moreover, in
keeping with a role for the N terminus of CARDINAL as the region
responsible for the observed effects on NF-
B activation, the
EGFP-CARDINAL-(1-320) mutant was as potent as full-length
EGFP-CARDINAL in repressing IL-1
- or TNF
-driven NF-
B reporter
gene activity under the same conditions (Fig. 7B).
(NEMO)--
Because CARDINAL could
antagonise NF-
B activation associated with engagement of multiple
independent receptor pathways (IL-1, TNF, TRAIL-R1/DR4, TRAIL-R2/DR5),
we considered it likely that CARDINAL intervened in these pathways at
their point of convergence, or beyond. Many studies have shown that
activation of the IKK complex is a key convergence point in divergent
signaling pathways that result in NF-
B activation (25-27). In
addition, recent studies have demonstrated that both RIP and RICK
promote NF-
B activation by direct binding to the regulatory subunit
of the IKK complex, IKK
/NEMO (23, 28, 29). Because CARDINAL could
antagonize NF-
B activation associated with transient overexpression
of either RIP or RICK (Fig. 5, A and B), this
suggested that CARDINAL may act at the level of IKK
/NEMO recruitment
by RICK or RIP, or at a point downstream of this.
,
providing a means whereby this CARD protein could antagonize multiple
independent NF-
B activation pathways. To explore this possibility,
HEK293T cells were co-transfected with expression plasmids encoding
IKK
, in combination with EGFP or EGFP-CARDINAL. 24 h after
transfection, cell lysates were made and CARDINAL was immunoprecipitated using an anti-CARDINAL polyclonal antibody. Immune
complexes were then probed for the presence of co-precipitated IKK
.
Fig. 8A illustrates that
IKK
was readily detectable in CARDINAL precipitates, suggesting that
CARDINAL directly interacts with this subunit of the IKK complex.
Additional co-immunoprecipitation experiments with the other components
of the IKK signalsome (IKK
, IKK
) revealed that CARDINAL
selectively co-precipitated IKK
(Fig. 8B). Furthermore,
co-immunoprecipitation experiments with CARDINAL and several
CARD-containing caspases (caspase-1, caspase-2, caspase-4, caspase-5,
and caspase-9) failed to find association between CARDINAL and the
latter molecules (data not shown). The ability of CARDINAL to interact
with IKK
/NEMO provides a molecular basis for the observed NF-
B
inhibitory effects of CARDINAL. Thus, CARDINAL may compete with other
CARD proteins, such as RICK and Bcl10, for recruitment of IKK
thereby antagonizing NF-
B activation in multiple independent
signaling pathways.

View larger version (34K):
[in a new window]
Fig. 8.
CARDINAL interacts with
IKK-
(NEMO). A, HEK293T cells
were transfected with 5 µg of T7 epitope-tagged IKK
, along with 5 µg of plasmids encoding EGFP or EGFP-CARDINAL, as indicated. 24 h after transfection, cells were lysed and CARDINAL was
immunoprecipitated with anti-CARDINAL polyclonal antibody, followed by
probing with horseradish peroxidase-linked anti-T7 monoclonal antibody
(Novagen) or anti-GFP monoclonal antibody
(CLONTECH), as shown. B, HEK293T cells
were transfected with 5 µg of the indicated T7 epitope-tagged IKK
expression plasmids, along with 5 µg of pcDNA3-CARDINAL, as
indicated. 24 h after transfection, cells were lysed and CARDINAL
was immunoprecipitated with anti-CARDINAL polyclonal antibody, followed
by probing with anti-T7 or anti-CARDINAL antibodies, as shown. The
asterisk represents immunoglobulin heavy chain; the
arrow indicates T7-tagged IKK
.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
B-inhibitory activity. CARDINAL was
found to associate with IKK
but not with several CARD-containing caspases. Consistent with this, CARDINAL failed to promote apoptosis but was found to antagonize NF-
B activation signals initiated by a
variety of receptors or their adaptors. During the preparation of this
report, CARDINAL was also reported by Reed and colleagues as TUCAN
(30). Although there is broad agreement on the domain structure, tissue
distribution, and failure of TUCAN to promote apoptosis, Reed's group
report that TUCAN can act as an antagonist of caspase-9 and can block
apoptosis associated with transient overexpression of Bax or
caspase-9/Apaf-1 (30). In contrast, our investigations along these
lines failed to find a role for CARDINAL/TUCAN as an inhibitor of
apoptosis, or an interaction partner for caspase-9 (data not shown).
Rather, we have found that CARDINAL/TUCAN antagonizes NF-
B
activation, a role that was not explored by Pathan et al.
(30). Some of the disagreement between the two groups may relate to the
expression systems/assays used. Clearly, further investigation of
CARDINAL/TUCAN, particularly at constitutive protein levels, will be
required to resolve these issues.
B activation (see Ref. 22 for a recent review). The
Bcl10 CARD protein appears to be a common convergence point for several
recently described CARD proteins that activate NF-
B (16, 18, 19).
Moreover, using BCL10-null mice, it has also been found that
Bcl10 is essential for NF-
B activation associated with stimulation
of the T or B cell receptors for antigen (20).
B activation appears to involve a distinct
set of CARD proteins, which includes members of the Nod1/Apaf-1 family.
Apaf-1 is a well established caspase-activating molecule that exhibits
homology with the Caenorhabditis elegans caspase-activating protein CED-4 (31). Apaf-1 possesses an N-terminal CARD motif, a
nucleotide-binding domain, and a domain rich in WD repeats that acts as
a sensor for cellular damage through binding of cytosolic cytochrome
c (9, 31). Upon binding of cytosolic cytochrome c
that has escaped from mitochondria through cell stress/damage, Apaf-1
acts as an oligomerization and activation platform for caspase-9.
Recently, two CARD-containing proteins with significant homology to
Apaf-1 (Nod1/CARD4 and Nod2) have been described that, in contrast to
Apaf-1, appear to be primarily involved in NF-
B activation through
recruitment of the RICK kinase (17, 23). Because RICK has been shown to
interact with IKK
, this suggests that aggregation of RICK by the
Apaf-1/Nod1-like family members may result in NF-
B activation
through downstream activation of the IKK complex via an induced
proximity mechanism (23).
B activation and a pro-inflammatory response
(in the case of Nod1/CARD4 and Nod2).
B activation, CARDINAL may act to counteract some of the latter molecules to set a
threshold for NF-
B activation. Alternatively, CARDINAL may play a
role in limiting the duration of NF-
B activation, through
competition with other proteins for IKK
/NEMO recruitment. Further
work is clearly necessary to explore how CARDINAL expression/stability is regulated in response to pro-inflammatory stimuli and to determine the specific biological context(s) in which CARDINAL operates.
B
activation signals in diverse contexts. This represents a novel
function for a CARD family protein and adds to the growing body of
evidence that proteins containing CARD motifs play diverse roles within
the overall context of host defense.
| |
ACKNOWLEDGEMENTS |
|---|
We thank Drs. Emad Alnemri, Vishva Dixit, David Goeddel, Doug Green, Gabriel Nunez, Jurg Tschopp, and Henning Walczak for valuable reagents.
| |
FOOTNOTES |
|---|
* This work was supported in part by Wellcome Trust Senior Fellowship Award in Biomedical Science 047580 and EU Grant QLG1-1999-00739 (to S. J. M. and M. M.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) AF405558.
§ Supported by Wellcome Trust Prize Studentship Award 055295.
To whom correspondence should be addressed. Tel.:
353-1-608-1289; Fax: 353-1-679-8558; E-mail:
martinsj@tcd.ie.
Published, JBC Papers in Press, September 10, 2001, DOI 10.1074/jbc.M107373200
| |
ABBREVIATIONS |
|---|
The abbreviations used are:
CARD, caspase
recruitment domain;
DED, death effector domain;
GST, glutathione
S-transferase;
GFP, green fluorescent protein;
EGFP, enhanced green
fluorescent protein;
IL, interleukin;
TNF, tumor necrosis factor;
PBS, phosphate-buffered saline;
IKK, I
B kinase.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Hofmann, K., Bucher, P., and Tschopp, J. (1997) Trends Biochem. Sci. 22, 155-156[CrossRef][Medline] [Order article via Infotrieve] |
| 2. | Martin, S. J., and Green, D. R. (1995) Cell 82, 349-352[CrossRef][Medline] [Order article via Infotrieve] |
| 3. | Earnshaw, W. C., Martins, L. M., and Kaufmann, S. H. (1999) Annu. Rev. Biochem. 68, 383-424[CrossRef][Medline] [Order article via Infotrieve] |
| 4. | Nicholson, D. W. (1999) Cell Death Differ. 6, 1028-1042[CrossRef][Medline] [Order article via Infotrieve] |
| 5. | Slee, E. A., Adrain, C., and Martin, S. J. (1999) Cell Death Differ. 6, 1067-1074[CrossRef][Medline] [Order article via Infotrieve] |
| 6. |
Slee, E. A.,
Adrain, C.,
and Martin, S. J.
(2001)
J. Biol. Chem.
276,
7320-7326 |
| 7. | Aravind, L., Dixit, V. M., and Koonin, E. V. (1999) Trends Biochem. Sci. 24, 47-53[CrossRef][Medline] [Order article via Infotrieve] |
| 8. | Kumar, S., and Colussi, P. A. (1999) Trends Biochem. Sci. 24, 1-4[CrossRef][Medline] [Order article via Infotrieve] |
| 9. | Adrain, C., and Martin, S. J. (2001) Trends Biochem. Sci. 26, 390-397[CrossRef][Medline] [Order article via Infotrieve] |
| 10. |
Salvesen, G. S.,
and Dixit, V. M.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
10964-10967 |
| 11. | Willis, T. G., Jadayel, D. M., Du, M. Q., Peng, H., Perry, A. R., Abdul-Rauf, M., Price, H., Karran, L., Majekodunmi, O., Wlodarska, I., Pan, L., Crook, T., Hamoudi, R., Isaacson, P. G., and Dyer, M. J. (1999) Cell 96, 35-45[CrossRef][Medline] [Order article via Infotrieve] |
| 12. |
Koseki, T.,
Inohara, N.,
Chen, S.,
Carrio, R.,
Merino, J.,
Hottiger, M. O.,
Nabel, G. J.,
and Nunez, G.
(1999)
J. Biol. Chem.
274,
9955-9961 |
| 13. |
Srinivasula, S. M.,
Ahmad, M.,
Lin, J. H.,
Poyet, J. L.,
Fernandes-Alnemri, T.,
Tsichlis, P. N.,
and Alnemri, E. S.
(1999)
J. Biol. Chem.
274,
17946-17954 |
| 14. |
Bertin, J.,
Nir, W. J.,
Fischer, C. M.,
Tayber, O. V.,
Errada, P. R.,
Grant, J. R.,
Keilty, J. J.,
Gosselin, M. L.,
Robison, K. E.,
Wong, G. H.,
Glucksmann, M. A.,
and DiStefano, P. S.
(1999)
J. Biol. Chem.
274,
12955-12958 |
| 15. |
Inohara, N.,
Koseki, T.,
del Peso, L.,
Hu, Y.,
Yee, C.,
Chen, S.,
Carrio, R.,
Merino, J.,
Liu, D.,
Ni, J.,
and Nunez, G.
(1999)
J. Biol. Chem.
274,
14560-14567 |
| 16. |
Bertin, J.,
Guo, Y.,
Wang, L.,
Srinivasula, S. M.,
Jacobson, M. D.,
Poyet, J. L.,
Merriam, S.,
Du, M. Q.,
Dyer, M. J.,
Robison, K. E.,
DiStefano, P. S.,
and Alnemri, E. S.
(2000)
J. Biol. Chem.
275,
41082-41086 |
| 17. |
Ogura, Y.,
Inohara, N.,
Benito, A.,
Chen, F. F.,
Yamaoka, S.,
and Nunez, G.
(2001)
J. Biol. Chem.
276,
4812-4818 |
| 18. |
Wang, L.,
Guo, Y.,
Huang, W. J.,
Ke, X.,
Poyet, J. L.,
Manji, G. A.,
Merriam, S.,
Glucksmann, M. A.,
DiStefano, P. S.,
Alnemri, E. S.,
and Bertin, J.
(2001)
J. Biol. Chem.
276,
21405-21409 |
| 19. |
Bertin, J.,
Wang, L.,
Guo, Y.,
Jacobson, M. D.,
Poyet, J. L.,
Srinivasula, S. M.,
Merriam, S.,
DiStefano, P. S.,
and Alnemri, E. S.
(2001)
J. Biol. Chem.
276,
11877-11882 |
| 20. | Ruland, J., Duncan, G. S., Elia, A., del Barco Barrantes, I., Nguyen, L., Plyte, S., Millar, D. G., Bouchard, D., Wakeham, A., Ohashi, P. S., and Mak, T. W. (2001) Cell 104, 33-42[CrossRef][Medline] [Order article via Infotrieve] |
| 21. |
Poyet, J. L.,
Srinivasula, S. M.,
and Alnemri, E. S.
(2001)
J. Biol. Chem.
276,
3183-3187 |
| 22. | Martin, S. J. (2001) Trends Cell Biol. 11, 188-189[CrossRef][Medline] [Order article via Infotrieve] |
| 23. |
Inohara, N.,
Koseki, T.,
Lin, J.,
del Peso, L.,
Lucas, P. C.,
Chen, F. F.,
Ogura, Y.,
and Nunez, G.
(2000)
J. Biol. Chem.
275,
27823-27831 |
| 24. |
Adrain, C.,
Slee, E. A.,
Harte, M. T.,
and Martin, S. J.
(1999)
J. Biol. Chem.
274,
20855-20860 |
| 25. | Yamaoka, S., Courtois, G., Bessia, C., Whiteside, S. T., Weil, R., Agou, F., Kirk, H. E., Kay, R. J., and Israel, A. (1998) Cell 93, 1231-1240[CrossRef][Medline] [Order article via Infotrieve] |
| 26. | Rothwarf, D. M., Zandi, E., Natoli, G., and Karin, M. (1998) Nature 395, 297-300[CrossRef][Medline] [Order article via Infotrieve] |
| 27. |
Rudolph, D.,
Yeh, W. C.,
Wakeham, A.,
Rudolph, B.,
Nallainathan, D.,
Potter, J.,
Elia, A. J.,
and Mak, T. W.
(2000)
Genes Dev.
14,
854-862 |
| 28. |
Poyet, J. L.,
Srinivasula, S. M.,
Lin, J. H.,
Fernandes-Alnemri, T.,
Yamaoka, S.,
Tsichlis, P. N.,
and Alnemri, E. S.
(2000)
J. Biol. Chem.
275,
37966-37977 |
| 29. | Zhang, S. Q., Kovalenko, A., Cantarella, G., and Wallach, D. (2000) Immunity 12, 301-311[CrossRef][Medline] [Order article via Infotrieve] |
| 30. |
Pathan, N.,
Marusawa, H.,
Krajewska, M.,
Matsuzawa, Si S.,
Kim, H.,
Okada, K.,
Torii, S.,
Kitada, S.,
Krajewski, S.,
Welsh, K.,
Pio, F.,
Godzik, A.,
and Reed, J. C.
(2001)
J. Biol. Chem.
276,
32220-32229 |
| 31. | Zou, H., Henzel, W. J., Liu, X., Lutschg, A., and Wang, X. (1997) Cell. 90, 405-413[CrossRef][Medline] [Order article via Infotrieve] |
| 32. |
Inohara, N.,
Ogura, Y.,
Chen, F. F.,
Muto, A.,
and Nunez, G.
(2001)
J. Biol. Chem.
276,
2551-2554 |
| 33. |
Chu, Z. L.,
Pio, F.,
Xie, Z.,
Welsh, K.,
Krajewska, M.,
Krajewski, S.,
Godzik, A.,
and Reed, J. C.
(2001)
J. Biol. Chem.
276,
9239-9245 |
| 34. |
Hlaing, T.,
Guo, R. F.,
Dilley, K. A.,
Loussia, J. M.,
Morrish, T. A.,
Shi, M. M.,
Vincenz, C.,
and Ward, P. A.
(2001)
J. Biol. Chem.
276,
9230-9238 |
This article has been cited by other articles:
![]() |
J. M. Wilmanski, T. Petnicki-Ocwieja, and K. S. Kobayashi NLR proteins: integral members of innate immunity and mediators of inflammatory diseases J. Leukoc. Biol., January 1, 2008; 83(1): 13 - 30. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Fontalba, V. Martinez-Taboada, O. Gutierrez, C. Pipaon, N. Benito, A. Balsa, R. Blanco, and J. L. Fernandez-Luna Deficiency of the NF-{kappa}B Inhibitor Caspase Activating and Recruitment Domain 8 in Patients with Rheumatoid Arthritis Is Associated with Disease Severity J. Immunol., October 1, 2007; 179(7): 4867 - 4873. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Wang, T. Chen, C. Han, D. He, H. Liu, H. An, Z. Cai, and X. Cao Lysosome-associated small Rab GTPase Rab7b negatively regulates TLR4 signaling in macrophages by promoting lysosomal degradation of TLR4 Blood, August 1, 2007; 110(3): 962 - 971. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. An, H. Xu, M. Zhang, J. Zhou, T. Feng, C. Qian, R. Qi, and X. Cao Src homology 2 domain-containing inositol-5-phosphatase 1 (SHIP1) negatively regulates TLR4-mediated LPS response primarily through a phosphatase activity- and PI-3K-independent mechanism Blood, June 15, 2005; 105(12): 4685 - 4692. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. C. Reed, K. S. Doctor, and A. Godzik The Domains of Apoptosis: A Genomics Perspective Sci. Signal., June 29, 2004; 2004(239): re9 - re9. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. S. Sathe, N. Sizemore, X. Li, K. Vithalani, M. Commane, S. M. Swiatkowski, and G. R. Stark Mutant human cells with constitutive activation of NF-{kappa}B PNAS, January 6, 2004; 101(1): 192 - 197. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. O'Connor Jr, J. A. Harton, X. Zhu, M. W. Linhoff, and J. P.-Y. Ting Cutting Edge: CIAS1/Cryopyrin/PYPAF1/NALP3/ CATERPILLER 1.1 Is an Inducible Inflammatory Mediator with NF-{k |